Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

REduced Dose Versus Full-dose of Direct Oral Anticoagulant After uNprOvoked Venous thromboEmbolism. The RENOVE Open-label, Randomized, Controlled Trial.

NCT03285438 is registered in ClinicalTrials.gov with University Hospital, Brest as lead sponsor.

NCT NCT03285438
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03285438 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
REduced Dose Versus Full-dose of Direct Oral Anticoagulant After uNprOvoked Venous thromboEmbolism. The RENOVE Open-label, Randomized, Controlled Trial.
Lead sponsor
University Hospital, Brest
Phase
Phase 3
Overall status
Completed
Start date
November 2, 2017
Completion date
November 8, 2023
Enrollment
2,774 (actual)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

venous thromboembolism